A Single-center, Single-blind, Randomized Controlled Clinical Study of Bowel Preparation Before Colonoscopy

DZQH-KYLL-23-11

This study was a single-center, randomized controlled clinical study. Subjects meeting the inclusion criteria will be randomly assigned to magnesium sodium potassium sulfate oral concentrated solution group, magnesium sodium potassium sulfate oral concentrated solution + linaclotide group, PEG group in equal proportion.

2023-08-01

2024-08-01

2024-08-01

Recruiting

444

Inclusion Criteria: * Signed written informed consent; * Age 18-80 years old, gender is not limited; * The subjects could follow the follow-up plan, objectively describe the symptoms, and cooperate with the completion of the scale; * Non-lactating pregnant women and no pregnancy plan during the test; * Do not participate in any clinical trials for 3 months before and during the trial; * Participate voluntarily and sign informed consent. Exclusion Criteria: * NYHA cardiac function grade III or IV; * Unstable angina pectoris in the convalescence period of acute myocardial infarction or in the near future; * have serious liver and kidney function diseases; * Suspected gastrointestinal obstruction or gastrointestinal perforation; * Pregnant or lactating women; * Mental illness or physical dysfunction can not cooperate with the examination; * People who are allergic to intestinal preparation drugs. * Patients who did not undergo colonoscopy after bowel clearing due to their own reasons; * Patients who can not tolerate general colonoscopy and terminate the examination; * Patients who requested withdrawal from the study.

{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'SINGLE', 'whoMasked': ['INVESTIGATOR']}}, 'enrollmentInfo': {'count': 444, 'type': 'ESTIMATED'}}

2023-10-23